The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 8, Issue 1, 2010, Pages 47-54

  Petrovic D ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Atherothrombotic disorders; Coronary artery disease; Gene therapy.; Genetic marker; Vascular endothelial growth factor gene

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACUTE HEART INFARCTION; ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GENE THERAPY; GENETIC POLYMORPHISM; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; NEOPLASM; NONHUMAN; PATHOGENESIS; RESTENOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; GENE THERAPY; GENETIC MARKERS; HUMANS; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950815770     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152510790796183     Document Type: Review

References (75)

1. Adamis, A.P.; Miller, J.W.; Bernal, M.T.; D'Amico, D.J.; Folk-man, J.; Yeo, T.K. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol, 1994, 118, 445.
2. Aiello, L.P.; Avery, R.L.; Arrigg, P.G.; Keyt, B.A.; Jampel, H.D.; Shah, S.-T.; Pasquale, L.R.; Thieme, H.; Iwamoto, M.A.; Park, J.E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 1994, 331, 1480.
3. Petrovic, M.G.; Korosec, P.; Kosnik, M.; Hawlina, M. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol., 2007, 143, 175.
4. Petrovic, M.G.; Korosec, P.; Kosnik, M.; Osredkar, J.; Hawlina, M.; Peterlin, B.; Petrovic, D. Local and genetic determinants of vascular endothelial growth factor expression in advanced prolif-erative diabetic retinopathy. Mol. Vis., 2008, 14, 1382.
5. Petrovic, D.; Verhovec, R.; Globocnik Petrovic, M.; Osredkar, J.; Peterlin, B. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology, 2007, 107, 291.
6. Silvestre, J.S.; Tamarat, R.; Ebrahimian, T.G.; Le-Roux, A.; Clergue, M.; Emmanuel, F.; Duriez, M.; Schwartz, B.; Branellec, D.; Levy, B.I. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ. Res., 2003, 93, 114.
7. Simari, R.D.; O'Brien, T. Clinical trials in vascular gene therapy: the missing piece of the puzzle. Arch. Pathol. Lab. Med., 2002, 126, 317.
8. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669.
9. Ruhrberg, C. Growing and shaping the vascular tree: multiple roles for VEGF. BioEssays, 2003, 25, 1052.
10. Tammela, T.; Zarkada, G.; Wallgard, E.; Murtomäki, A.; Suchting, S.; Wirzenius, M.; Waltari, M.; Hellström, M.; Schomber, T.; Peltonen, R.; Freitas, C.; Duarte, A.; Isoniemi, H.; Laakkonen, P.; Christofori, G.,; Ylä-Herttuala, S.; Shibuya, M.; Pytowski, B.; Eichmann, A.; Betsholtz, C.; Alitalo, K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature, 2008, 454, 656.
11. Ferrara, N. The biology of vascular endothelial growth factor. Endocr. Rev., 1997, 18, 4.
12. Hofstaetter, J.G.; Saad, F.A.; Sunk, I.G.; Bobacz, K.; Friehs, I.; Glimcher, M.J. Age-dependent expression of VEGF isoforms and receptors in the rabbit anterior cruciate ligament. Biochim. Biophys. Acta, 2007, 1770, 997.
13. Konopatskaya, O.; Churchill, A.J.; Harper, S.J.; Bates, D.O.; Gardiner, T.A. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol. Vis., 2006, 12, 626.
14. Shen, W.Y.; Lai, C.M.; Graham, C.E.; Binz, N.; Lai, Y.K.; Eade, J.; Guidolin, D.; Ribatti, D.; Dunlop, S.A.; Rakoczy, P.E. Longterm global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model. Diabetologia, 2006, 49, 1690.
15. Zygalaki, E.; Kaklamanis, L.; Nikolaou, N.I.; Kyrzopoulos, S.; Houri, M.; Kyriakides, Z.; Lianidou, E.S.; Kremastinos, D.T. Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease. Clin. Biochem., 2008, 41, 82.
16. Chou, E.; Suzuma, I.; Way, K.J.; Opland, D.; Clermont, A.C.; Naruse, K.; Suzuma, K.; Bowling, N.L.; Vlahos, C.J.; Aiello, L.P.; King, G.L. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation, 2002, 105, 373.
17. Sasso, F.C.; Carbonara, O.; Persico, E.; D'Ambrosio, R.; Coppola, L.; Nasti, R.; Campana, B.; Moschella, S.; Torella, R.; Cozzolino, D. Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats. Metabolism, 2003, 52, 675.
18. Sasso, F.C.; Torella, D.; Carbonara, O.; Ellison, G.M.; Torella, M.; Scardone, M.; Marra, C.; Nasti, R.; Marfella, R.; Cozzolino, D.; Indolfi, C.; Cotrufo, M.; Torella, R.; Salvatore, T. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J. Am. Coll. Cardiol., 2005, 46, 827.
19. Marfella, R.; Esposito, K.; Nappo, F.; Siniscalchi, M.; Sasso, F.C.; Portoghese, M.; Di Marino, M.P.; Baldi, A.; Cuzzocrea, S.; Di Filippo, C.; Barboso, G.; Baldi, F.; Rossi, F.; D'Amico, M.; Giugliano, D. Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes, 2004, 53, 2383.
20. Shiojima. I.; Walsh, K. Role of Akt signaling in vascular homeo-stasis and angiogenesis. Circ. Res., 2002, 90, 1243.
21. Murohara, T.; Asahara, T.; Silver, M.; Bauters, C.; Masuda, H.; Kalka, C.; Kearney, M.; Chen, D.; Symes, J.F.; Fishman, M.C.; Huang, P.L.; Isner, J.M. Nitric oxide synthase modulates angio-genesis in response to tissue ischemia. J. Clin. Invest. 1998, 101, 2567.
22. Kroll, J.; Waltenberger, J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem. Biophys. Res. Commun., 1998, 252, 743.
23. Kuwabara. M.; Kakinuma, Y.; Ando, M.; Katare, R.G.; Yamasaki, F.; Doi, Y.; Sato, T. Nitric oxide stimulates vascular endothelial growth factor production in cardiomyocytes involved in angiogenesis. J. Physiol. Sci. 2006, 56, 95.
24. Van der Zee, R.; Murohara, T.; Luo, Z.; Zollmann, F.; Passeri, J.; Lekutat, C.; Isner, J.M. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation, 1997, 95, 1030.
25. Morbedelli, L.; Chang, C.H.; Douglas, J.G. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am. J. Physiol. Heart Circ., 1996, 270, H411.
26. Papapetropoulos, A.; Garcia-Cardena, G.; Madri, J.A.; Sessa, W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest., 1997, 100, 3131.
27. Waltenberger, J.; Lange, J.; Kranz, A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation, 2000, 102, 185.
28. Marchand, G.S.; Noiseux, N.; Tanguay, J.F.; Sirois, M.G. Blockade of in vivo VEGF-mediated angiogenesis by antisense gene therapy: role of Flk-1 and Flt-1 receptors. Am. J. Physiol. Heart Circ. Physiol. 2002, 282(1), H194.
29. Tamarat, R.; Silvestre, J.S.; Huijberts, M.; Benessiano, J.; Ebra-himian, T.G.; Duriez, M.; Wautier, M.P.; Wautier, J.L.; Lévy, B.I. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc. Natl. Acad. Sci. USA, 2003, 100, 8555.
30. Duraisamy, Y.; Slevin, M.; Smith, N.; Bailey, J.; Zweit, J.; Smith, C.; Ahmed, N.; Gaffney, J. Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis, 2001, 4, 277.
31. Cao, R.; Eriksson, A.; Kubo, H.; Alitalo, K.; Cao, Y.; Thyberg, J. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ. Res., 2004, 94, 664.
32. Murakami, M.; Nguyen, L.T.; Zhang, Z.W.; Moodie, K.L.; Carmeliet, P.; Stan, R.V.; Simons, M. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest., 2008, 118, 3355.
33. Lindahl, B.; Toss. H.; Siegbahn, A.; Venge, P.; Wallentin, L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease: FRISC Study Group. Fragmin during instability in coronary artery disease. N. Engl. J. Med., 2000, 343, 1139.
34. Lee, K.W.; Lip, G.Y.; Blann, A.D. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation, 2004, 110, 2355.
35. Lee, S.H.; Wolf, P.L.; Escudero, R.; Deutsch, R.; Jamieson, S.W.; Thistlethwaite, P.A. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N. Engl. J. Med., 2000, 342, 626.
36. Ogawa, H.; Suefuji, H.; Soejima, H.; Nishiyama, K.; Misumi, K.; Takazoe, K.; Miyamoto, S.; Kajiwara, I.; Sumida, H.; Sakamoto, T.; Yoshimura, M.; Kugiyama, K.; Yasue, H.; Matsuo, K. Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction. Cardiology, 2000, 93, 93.
37. Heeschen, C.; Dimmeler, S.; Hamm, C.W.; Boersma, E.; Zeiher, A.M.; Simoons, M.L. CAPTURE (c7E3 Anti-platelet therapy in unstable refractory angina) investigators. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation, 2003, 107, 524.
38. Weigand, M.A.; Hörner, C.; Bardenheuer, H.J.; Bouchon, A. The systemic inflammatory response syndrome. Best Pract. Res. Clin. Anaesthesiol., 2004, 18, 455.
39. Denizot, Y.; Guglielmi, L.; Cornu, E.; Nathan, N. Alterations in plasma angiogenic growth factor concentrations after coronary artery bypass graft surgery: relationships with post-operative complications. Cytokine, 2003, 24, 7.
40. Denizot, Y.; Leguyader, A.; Cornu, E.; Laskar, M.; Orsel, I.; Vincent, C.; Nathan, N. Alterations in plasma soluble vascular endo-thelial growth factor receptor-1 (sFlt-1) concentrations during coronary artery bypass graft surgery: relationships with postoperative complications. Cardiothorac. Surg., 2008, 3, 16.
41. Brogan, I.J.; Khan, N.; Isaac, K.; Hutchinson, J.A.; Pravica, V.; Hutchinson, I.V. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol., 1999, 60, 1245.
42. Awata, T.; Inoue, K.; Kurihara, S.; Watanabe, M.; Inukai, K.; Inoue, I.; Katayama, S. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes, 2002, 51, 1635.
43. Van der Meer, P.; De Boer, R.A.; White, H.L.; Van der Steege, G.; Hall, A.S.; Voors, A.A.; Van Veldhuisen, D.J. The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J. Card. Fail., 2005, 11, 279.
44. Ray, D.; Mishra, M.; Ralph, S.; Read, I.; Davies, R.; Brenchley, P. Association of the VEGF gene with proliferative diabetic retinopa-thy but not proteinuria in diabetes. Diabetes, 2004, 53, 861.
45. Huez, I.; Bornes, S.; Bresson, D.; Creancier, L.; Prats, H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol. Endocrinol., 2001, 15, 2197.
46. Inoue, M.; Itoh, H.; Ueda, M.; Naruko, T.; Kojima, A.; Komatsu, R.; Doi, K.; Ogawa, Y.; Tamura, N.; Takaya, K.; Igaki, T.; Yama-shita, J.; Chun, T.-U.; Masatsugu, K.; Anton E. Becker, A.E.; Na-kao, K. Vascular endothelial growth factor expresion in human coronary atherosclerotic lesions: possible pathophysiologiocal significance of VEGF in progresion of atherosclerosis. Circulation, 1998, 98, 2108.
47. Kangas-Kontio, T.; Tapanainen, J.M.; Huikuri, H.; Savolainen, E.R.; Paivansalo, M.; Kauma, H.; Antero Kesaniemi, Y.; Savolainen, M.J.; Kakko, S. Variation in the vascular endothelial growth factor gene, carotid intima-media thickness and the risk of acute myocardial infarction. Scand. J. Clin. Lab. Invest., 2009, 69(3), 335.
48. Alioglu, E.; Turk, U.; Cam, S.; Abbasaliyev, A.; Tengiz, I.; Ercan, E. Polymorphisms of the methylenetetrahydrofolate reductase, vascular endothelial growth factor, endothelial nitric oxide synthase, monocyte chemoattractant protein-1 and apolipoprotein E genes are not associated with carotid intima-media thickness. Can. J. Cardiol., 2009, 25, e1.
49. Howell, W.M.; Ali, S., Rose-Zerilli, M.J.; Ye, S. VEGF polymorphisms and severity of atherosclerosis. J. Med. Genet., 2005, 42, 485.
50. Douvaras, P.; Antonatos, D.G.; Kekou, K.; Patsilinakos, S.; Chouliaras, G.; Christou, A.; Andrikou, A.; Kanavakis, E. Association of VEGF Gene Polymorphisms with the Development of Heart Failure in Patients after Myocardial Infarction. Cardiology, 2009, 114, 11.
51. Fuchs, S.; Battler, A.; Kornowski, R. Catheter-based stem cell and gene therapy refractory myocardial ischemia. Nat. Clin. Pract. Cardiovasc. Med., 2007, 4, S89.
52. Thom, T.; Haase, N.; Rosamond, W.; Howard, V.J.; Rumsfeld, J.; Manolio, T.; Zheng, Z.J.; Flegal, K.; O'Donnell, C.; Kittner, S.; Lloyd-Jones, D.; Goff, D.C., Jr.; Hong, Y.; Adams, R.; Friday, G.; Furie, K.; Gorelick, P.; Kissela, B.; Marler, J.; Meigs, J.; Roger, V.; Sidney, S.; Sorlie, P.; Steinberger, J.; Wasserthiel-Smoller, S.; Wilson, M.; Wolf, P. American Heart Association Statistic Committee Stroke Statistics Subcommittee. Heart disease and stroke statistic 2006 update: a report from the American Heart Association Statistics Committee and stroke statistics subcommittee. Circulation, 2006, 113, e85.
53. Sharif, F.; Daly, K.; Crowley, J.; O'Brien, T. Current status of catheter-and stent-based gene therapy. Cardiovasc. Res., 2004, 64, 208.
54. Sharif, F.; Hynes, S.O.; McMahon, J.; Cooney, R.; Conroy, S.; Dockery, P.; Duffy, G.; Daly, K.; Crowley, J.; Bartlett, J.S.; Timothy O'Brien, T. Gene-eluting stents: comparison of adenoviral and adenoassociated viral gene delivery to the blood vessel wall in vivo. Hum. Gene Ther., 2006, 17, 741.
55. Walter, D.H.; Cejna, M.; Diaz-Sandoval, L.; Willis, S.; Kirkwood, L.; Stratford, P.W.; Tietz, A.B.; B.S; Kirchmair, R.; Silver, M.; Curry, C.; Wecker, A.; Yoon, Y.S.; Heidenreich, R.; Hanley, A.; Kearney, M.; Tio, F.O.; Kuenzler, P.; Isner, J.M.; Losordo, D.W. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation, 2004, 110, 36.
56. Johnson, T.W.; Wu, Y.X.; Herdeg, C.; Baumbach, A.; Newby, A.C.; Karsch, K.R.; Oberhoff, M. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 754.
57. Laitinen, M.; Hartikainen, J.; Hiltunen, M.O.; Eranen, J.; Kiviniemi, M.; Narvanen, O.; Mäkinen, K.; Manninen, H.; Syvänne, M.; Martin, J.F.; Laakso, M.; Ylä-Herttuala, S. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene. Ther., 2000, 11, 263.
58. Hedman, M.; Hartikainen, J.; Syvanne, M.; Stjernvall, J.; Hedman, A.; Kivela, A.; Kivelä, A.; Vanninen, E.; Mussalo, H.; Kauppila, E.; Simula, S.; Närvänen, O.; Rantala, A.; Peuhkurinen, K.; Nieminen, M.S.; Seppo M.L.; Ylä-Herttuala. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation, 2003, 107, 2677.
59. Hedman, M.; Muona, K.; Hedman, A.; Kivelä, A.; Syvänne, M.; Eränen, J.; Rantala, A.; Stjernvall, J.; Nieminen, M.S.; Hartikainen, J.; Ylä-Herttuala, S. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther., 2009, 16(5), 629.
60. Stewart, D.J.; Kutryk, M.J.; Fitchett, D.; Freeman, M.; Camack, N.; Su, Y.; Della Siega, A.; Bilodeau, L.; Burton, J.R.; Proulx, G.; Radhakrishnan, S.; NORTHERN Trial Investigators.VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol. Ther., 2009, 17, 1109.
61. Kastrup, J.; Jørgensen, E.; Rück, A.; Tägil, K.; Glogar, D.; Ruzyllo, W.; Bøtker, H.E.; Dudek, D.; Drvota, V.; Hesse, B.; Thuesen, L.; Blomberg, P.; Gyöngyösi, M.; Sylvén, C.; Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol., 2005, 45, 982.
62. Mannheimer, C.; Camici, P.; Chester, M.R.; Collins, A.; DeJongste, M.; Eliasson, T.; Follath, F.; Hellemans, I.; Herlitz, J.; Luscher, T.; Pasic, M.; Thelle, D. The problem of chronic refractory angina: report from the ESC Joint Study Group on the Treatment of refractory angina. Eur. Heart J., 2002, 23, 355.
63. Menasche, P.; Hagege, A.A.; Vilquin, J.T.; Desons, M.; Abergel, E.; Pozet, B.; Bel, A.; Sarateanu, S.; Scorsin, M.; Schwartz, K.; Bruneval, P.; Benbunan, M.; Marolleau, J.P.; Duboc, D. Autologus skeletal myoblast transplantation for severe post infarction left ventricular dysfunction. J. Am. Coll. Cardiol., 2003, 41, 1078.
64. Fernandes, S.; Amirault, J.C.; Lande, G.; Nguyen, J.M.; Forest, V.; Bignolais, O.; Lamirault, G.; Heudes, D.; Orsonneau, J.L.; Heymann, M.F.; Charpentier, F.; Lemarchand, P. Autologus myoblast after myocardial infarction increases the inducibility of ventricular arrhythmias. Cardiovasc. Res., 2006, 69, 348.
65. Fouts, K.; Fernandes, B.; Mal, N.; Liu, J.; Laurita, K.R. Electro-physiological consequence of skeletal myoblast transplantation in normal and infarcted canine myocardium. Heart Rhythm., 2006, 3, 452.
66. Ripa, R.S.; Wang, Y.; Jorgensen, E.; Johnsen, H.E.; Hesse, B.; Kastrup, J. Intramyocardial injection of vascular endothelium growth factor-A165 plasmid followed by granulocyte-colony stimulating factor treatment to mobilize stem cells and promote myocardial homing to induce angiogenesis in patients with severe chronic ischemic heart disease. Eur. Heart J., 2006, 27, 1785.
67. Baldazzi, F.; Jørgensen, E.; Ripa, R.S.; Kastrup, J. Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route. Eur. Heart J., 2008, 29, 1819.
68. Bai, X.; Sadat, S.; Gehmert, S.; Alt, E.; Song, Y.H. VEGF receptor Flk-1 plays an important role in c-kit expression in adipose tissue derived stem cells. FEBS. Lett., 2007, 581, 4681.
69. Rehman, J.; Traktuev, D.; Li, J.; Merfeld-Clauss, S.; Temm-Grove, C.J.; Bovenkerk, J.E.; Pell, C.L.; Johnstone, B.H.; Considine, R.V.; March, K.L. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation, 2004, 109, 1292.
70. Miranville, A.; Heeschen, C.; Sengenes, C.; Curat, C.A.; Busse, R.; Bouloumie, A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation, 2004, 110, 349.
71. Planat-Benard, V.; Silvestre, J.S.; Cousin, B.; Andre, M.; Nibbelink, M.; Tamarat, R. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation, 2004, 109, 656.
72. Sasano, T.; Kikuchi, K.; McDonald, A.D.; Lai, S.; Donahue, J.K. Targeted high-efficiency, homogeneous myocardial gene transfer. J. Mol. Cell Cardiol., 2007, 42, 954.
73. Ledley, F.D. Non-viral gene therapy. Curr. Opin. Biotechnol., 1994, 5, 626
74. Gaffney, M.M.; Hynes, S.O.; Barry, F.; O'Brien, T. Cardiovascular gene therapy: current status and therapeutic potential. Br. J. Pharmacol., 2007, 152, 175.
75. Müller, O.J.; Katus, H.A.; Bekeredjian, R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc. Res., 2007, 73, 453.